Epizyme Inc., of Cambridge, Mass., said it dosed the first patient in a phase II trial of lead candidate tazemetostat (EPZ-6438) in patients with relapsed or refractory non-Hodgkin lymphoma. Read More
The Biotechnology Industry Organization (BIO) issued a statements opposing an amendment to the 21st Century Cures Initiative legislation filed by Rep. Dave Brat (R-Va.) that would convert the mandatory funding for the NIH to discretionary funding. Read More
Porton Biopharma Ltd., of Salisbury, UK, was spun out of Public Health England's clinical drug development and production capability into a standalone, state-owned biopharmaceutical limited company that has been approved by the Secretary of State for Health. Read More
Clovis Oncology Inc., of Boulder, Colo., said it priced an underwritten public offering of 3.5 million shares of its common stock at $78 each for gross proceeds of $275 million. Read More
Nusirt Biopharma Inc. is a small biotech that has largely avoided the limelight, but ambitious goals to attack two major indications – type 2 diabetes and nonalcoholic steatohepatitis (NASH) – could quickly raise its profile. Read More
Globavir Biosciences Inc. found a partner for its lead oncology program in Sorrento Therapeutics Inc., which in turn inked another in a string of deals with the oncology syndicate Nantworks LLC that is being assembled by founder Patrick Soon-Shiong. Read More
Marginal. Modest. Incremental. That's how the FDA and members of its Oncologic Drugs Advisory Committee (ODAC) described the 1.6-month improvement in overall survival (OS) Eli Lilly and Co.'s necitumumab demonstrated in a pivotal trial as a first-line treatment for squamous NSCLC. Read More
HONG KONG – A dramatic plummeting in the value of publicly listed shares in Mainland China over the last month has wiped out roughly $3 trillion in wealth and raised fears of a collapse in the country's stock market, a collapse that could exacerbate slowing economic growth. Read More
